Breaking Finance News

A statement released earlier today by RBC Capital Markets about Shire PLC (ADR) (NDAQ:SHPG) bumps the target price to $213.00

Boasting a price of $152.20, Shire PLC (ADR) (NDAQ:SHPG) traded 0.84% higher on the day. The last stock price is down -8.46% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the same period. SHPG has recorded a 50-day average of $152.69 and a two hundred day average of $165.51. Trading volume was down over the average, with 668,007 shares of SHPG changing hands under the typical 1,235,810

RBC Capital Markets bumped up the target of Shire PLC (ADR) (NDAQ:SHPG) to $213.00 stating a potential upside of 0.40%.

On Thursday August 17, 2017, Evercore ISI released a statement for Shire PLC (ADR) (NDAQ:SHPG) bumped up the target price from $0.00 to $196.00 that suggested an upside of 0.32%.

Performance Chart

Shire PLC (ADR) (NDAQ:SHPG)

With a total market value of $0, Shire PLC (ADR) has price-earnings ratio of 67.79 with a one year low of $139.36 and a one year high of $192.64 .

A total of 14 equity analysts have released a ratings update on SHPG. Seven equity analysts rating the company a strong buy, seven equity analysts rating the company a buy, two equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $241.86.

Brief Synopsis About Shire PLC (ADR) (NDAQ:SHPG)

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *